BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vifor Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Vifor Pharma's drugs run\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05003986-10808@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270312
DTEND;VALUE=DATE:20270313
SUMMARY:Filspari (sparsentan): Phase 2 readout est. (NCT05003986)
DESCRIPTION:Filspari (sparsentan)\, phase 2\, Focal Segmental Glomeruloscle
 rosis.\nStudy: Study of Sparsentan Treatment in Pediatrics With Proteinuri
 c Glomerular Diseases\nEstimated primary completion: 12 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sparsentan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05003986
URL:https://assetmemo.bio/drug/sparsentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06321601-955@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270718
DTEND;VALUE=DATE:20270719
SUMMARY:Tavneos (Avacopan): Phase 3 readout est. (NCT06321601)
DESCRIPTION:Tavneos (Avacopan)\, phase 3.\nStudy: Study to Evaluate Avacopa
 n in Combination With a Rituximab or Cyclophosphamide-containing Regimen\,
  in Children From 6 Years to < 18 Years of Age With AAV.\nEstimated primar
 y completion: 18 July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/avacopan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06321601
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494045-881@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Rayaldee (Extended-release calcifediol): Phase 2 readout est. (NCT0
 7494045)
DESCRIPTION:Rayaldee (Extended-release calcifediol)\, phase 2\, Chronic Kid
 ney Disease.\nStudy: Pharmacokinetics\, Pharmacodynamics\, Safety and Tole
 rability Evaluation of CTAP101 Extended-release Capsules in Pediatric Part
 icipants\nEstimated primary completion: October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/extended-release-calcifediol#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07494045
URL:https://assetmemo.bio/drug/extended-release-calcifediol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06593392-883@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Korsuva (Difelikefalin): Phase 2 readout est. (NCT06593392)
DESCRIPTION:Korsuva (Difelikefalin)\, phase 2\, Chronic Kidney Disease.\nSt
 udy: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialy
 sis With Moderate-to-Severe Pruritus\nEstimated primary completion: 15 Aug
 ust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/difelikefal
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6593392
URL:https://assetmemo.bio/drug/difelikefalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05766839-607@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Veltassa (Patiromer): Phase 2 readout est. (NCT05766839)
DESCRIPTION:Veltassa (Patiromer)\, phase 2.\nStudy: Effect of Patiromer in 
 Children Under 12 Years of Age With High Blood Potassium Levels\nEstimated
  primary completion: 1 December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/patiromer#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05766839
URL:https://assetmemo.bio/drug/patiromer#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
